TransMed7, LLC Announces First Clinical Use of Heron Soft Tissue Biopsy Devices for Commercial Launch
Retrieved on:
Tuesday, August 16, 2022
Biotechnology, Surgery, Medical Devices, Health, Oncology, FDA, Liver, Cardiovascular disease, Cardiovascular and Interventional Radiological Society of Europe, BPH, RSNA, CEO, College of Medicine, Diagnosis, Breast, Technology, Heron, Clinical, Needle, WCU, Regenerative medicine, XPK, LLC, Federal Food, Drug, and Cosmetic Act, Atlantic Film Festival, Patient, Prostate, Lymph, Globe, Skin, Architecture, RO, XP, Radiological Society of North America, Kidney, Histopathology, Phoenix, Arizona, Physician, XPS, Lung, University, McKesson Corporation, Solution, Blood, Neuro, RCU, Biopsy, Medicine, Medical imaging, Medical device
The whole biopsy procedure was finished in less than 5 minutes, which represents a significant cost savings as well.
Key Points:
- The whole biopsy procedure was finished in less than 5 minutes, which represents a significant cost savings as well.
- The Heron platform of soft tissue biopsy devices includes three models of hand-held, ultrasound guided, vacuum assisted, full fluid management, SIMC devices.
- The Heron XPK and XPS full featured models are designed for manual coring length control and automatic tissue transport.
- The Heron platform devices will provide the most advanced capabilities for biopsy devices featuring needle sizes from 12 to 18 gauge.